Scholarlink

Background <p>The prognosis prediction of breast cancer is a challenging problem in the clinic. Identifying reliable biomarkers and revealing the regulatory mechanism underlying the progression of breast cancer cells would benefit the treatment and outcomes of breast cancer patients.</p> Objectives <p>This study aims to explore a novel biomarker related with tumor progression and clinical prognosis, focusing on miR-4793-3p and its targets.</p> Materials and methods <p>The study enrolled 133 patients with breast cancer, and tissue samples were obtained. Expression of miR-4793-3p and its clinical significance were evaluated from the perspective of molecular subtypes, disease development, and prognosis. The regulatory effect and mechanism of miR-4793-3p in the biological function of breast cancer cells were assessed.</p> Results <p>Significant downregulation of miR-4793-3p was observed in tumor tissues of patients with breast cancer, and lower miR-4793-3p levels were found in patients with more malignant subtypes. miR-4793-3p was closely associated with the differentiation, TNM stage, lymph node metastasis, subtypes, and poor prognosis of patients and was identified as an independent prognostic factor. miR-4793-3p significantly suppressed cell growth, metastatic potential, and promoted ferroptosis of breast cancer, and the negative regulation of <i>RNF169</i> was revealed to mediate the function of miR-4793-3p. JAK2/STAT3 signaling was suppressed by miR-4793-3p, which suppressed cell growth and metastatic potential and promoted ferroptosis.</p> Conclusion <p>miR-4793-3p could act as a biomarker for breast cancer, indicating cancer development and predicting patients’ outcomes. miR-4793-3p modulated ferroptosis and therefore regulated tumor progression via suppressing JAK2/STAT3 signaling by targeting <i>RNF169</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

miR-4793-3p predicts poor prognosis and regulates ferroptosis and invasiveness of breast cancer via targeting RNF169

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Yan Chang,
  • Zhemin Sun,
  • Meiling Xu

摘要

Background

The prognosis prediction of breast cancer is a challenging problem in the clinic. Identifying reliable biomarkers and revealing the regulatory mechanism underlying the progression of breast cancer cells would benefit the treatment and outcomes of breast cancer patients.

Objectives

This study aims to explore a novel biomarker related with tumor progression and clinical prognosis, focusing on miR-4793-3p and its targets.

Materials and methods

The study enrolled 133 patients with breast cancer, and tissue samples were obtained. Expression of miR-4793-3p and its clinical significance were evaluated from the perspective of molecular subtypes, disease development, and prognosis. The regulatory effect and mechanism of miR-4793-3p in the biological function of breast cancer cells were assessed.

Results

Significant downregulation of miR-4793-3p was observed in tumor tissues of patients with breast cancer, and lower miR-4793-3p levels were found in patients with more malignant subtypes. miR-4793-3p was closely associated with the differentiation, TNM stage, lymph node metastasis, subtypes, and poor prognosis of patients and was identified as an independent prognostic factor. miR-4793-3p significantly suppressed cell growth, metastatic potential, and promoted ferroptosis of breast cancer, and the negative regulation of RNF169 was revealed to mediate the function of miR-4793-3p. JAK2/STAT3 signaling was suppressed by miR-4793-3p, which suppressed cell growth and metastatic potential and promoted ferroptosis.

Conclusion

miR-4793-3p could act as a biomarker for breast cancer, indicating cancer development and predicting patients’ outcomes. miR-4793-3p modulated ferroptosis and therefore regulated tumor progression via suppressing JAK2/STAT3 signaling by targeting RNF169.